vanzacaftor   Click here for help

GtoPdb Ligand ID: 13694

Synonyms: VX-121 | VX121
Approved drug
vanzacaftor is an approved drug
Compound class: Synthetic organic
Comment: Vanzacaftor (VX-121) is a cystic fibrosis transmembrane regulator (CFTR) protein modulator/corrector for class II CFTR mutations (the most common being F508del). The principal action of vanzacaftor is to restore the folding/trafficking of mutated CFTR to the plasma membrane. VX-121 also stimulates a K+ secretory current that is mediated by the large-conductance calcium-activated potassium channel (BKCa, KCa1.1) [2].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 11
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 136.44
Molecular weight 617.76
XLogP 4.91
No. Lipinski's rules broken 2

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1(C)C[C@@H]2CCCNC3=CC=CC(=N3)S(=O)(=O)NC(=O)C4=CC=C(N=C4N1C2)N5C=CC(=N5)OCCC6C7(CC7)C86CC8
Isomeric SMILES CC1(C[C@@H]2CCCNC3=NC(=CC=C3)S(=O)(=O)NC(=O)C4=C(N1C2)N=C(C=C4)N5C=CC(=N5)OCCC6C7(C68CC8)CC7)C
InChI InChI=1S/C32H39N7O4S/c1-30(2)19-21-5-4-16-33-24-6-3-7-27(34-24)44(41,42)37-29(40)22-8-9-25(35-28(22)38(30)20-21)39-17-10-26(36-39)43-18-11-23-31(12-13-31)32(23)14-15-32/h3,6-10,17,21,23H,4-5,11-16,18-20H2,1-2H3,(H,33,34)(H,37,40)/t21-/m0/s1
InChI Key VCSUIBJKYCVWNF-NRFANRHFSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, Kotsimbos T, Mermis J, Braun AT, O'Carroll M et al.. (2025)
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.
Lancet Respir Med, 13 (3): 256-271. [PMID:39756424]
2. Kolski-Andreaco A, Taiclet S, Myerburg MM, Sembrat J, Bridges RJ, Straub AC, Wills ZP, Butterworth MB, Devor DC. (2024)
Potentiation of BKCa channels by cystic fibrosis transmembrane conductance regulator correctors VX-445 and VX-121.
J Clin Invest, 134 (16). [PMID:38954478]